Oncology CRO | Charles River Discovery Research Services

Human Tumor Xenograft in Nude Mice 

Charles River Discovery Research Services enables clients to use their budgets efficiently through in vivo efficacy evaluation of potential cancer therapies in human xenograft tumor models. Our broad range of tumor lines ensures a wide variety of testing alternatives for your agent. Our xenograft model portfolio is evaluated on a regular basis for response to standards of care and this data is available for designing combination studies.

The xenograft cancer model of choice can be used, or our scientific staff can assist in selecting the most appropriate model for your agent. Complete profiling of agents can be carried out in a variety of tumor types or in combination with the appropriate clinical agent. Specially requested lines can be brought in if a tumor xenograft model of interest is not among those listed below:

Models with Standard of Care in vivo profile established

Histotype Cell Line
Bladder SW780
Brain SK-N-AS, U87 MG, U-251
Breast BT474, HCC-1954, JIMT-1, MCF-7,
MDA-MB-231, MX-1
Colon CL-34, COLO 205, DLD-1, HCT 116, HCT-15, HT-29, LoVo,
LS-174T, LS411N, RKO, SW-480, SW-620
Epithelial A-431
Gastric MKN-45, N87, SNU-5
Head and Neck FaDu
Leukemia HL-60, K-562, MOLT-4, MV4-11, SET2
Liver Hep3B, SNU-398
Lung (Non-small cell) A-427, A549, Calu-6, H1299,H1975, H226, H292, H460, H520, H522, H647, H727, H810, HCC-44, 
SK-MES-1, NCI-H2122
Lung (Small cell) H69, H82, H211, H526, SHP-77, DMS 114, H82
Lymphoma Daudi, DoHH-2, Granta 519, Namalwa, Raji B, Ramos,
REC-1, RL, SU-DHL-4, WSU-DLCL2
Melanoma A2058, A375, IGR-37, SK-MEL-5
Mesothelioma MSTO-211H
Multiple Myeloma H929, OPM-2, RPMI 8226
Ovarian A2780, IGR0V1, OVCAR-3, OVCAR-5, SK-OV-3,
TOV-21G
Pancreas BxPc-3, Capan-1, HPAC, KP4, MIA PaCa-2, PANC-1
Prostate 22Rv.1, DU 145, MDA-PCa2B, PC3
Renal 786-0, Caki-1, Caki-2, G-401, G-402
Sarcoma HT-1080, SJSA-1
Thyroid 8505C, FTC-238
Uterine ECC-1, MFE-280

In vivo Established Models with Standard of Care profile not yet available

Histotype Cell Line
Adrenal H295R
Bladder RT112
Brain SF-295, SK-N-MC
Breast HCC70, HCC-1806
Leukemia HEL92.1.7, RS4;11, SET2, THP-1
Liver HuH-7
Lung COR-L23, NCI-H1963, H2009, H1581, H1993
Melanoma CHL-1, COLO 800, IGR-1, IGR-37, SK-MEL-24,
UACC-62
Thyroid K1
Uterine HEC-1-A, HEC-1-B

 

Efficacy evaluation can be combined with:

  • Hematology (CBC/Diff) analysis
  • Pharmacokinetic or bioavailability sampling and analysis
  • Histopathology or tissue sampling
  • Biomarker screening, sampling or evaluation


 Data

Individual Times to End Point for HT29 Xenografts Growing in Female Nude Mice (Days vs treatment)


Individual Times to End Point for HT29 Xenografts Growing in Female Nude Mice (Days vs treatment)


  

Individual Times to End Point for HT29 Xenografts Growing in Female Nude Mice (Median tumor volume vs days)


Individual Times to End Point for HT29 Xenografts Growing in Female Nude Mice (Median tumor volume vs days)

 

Kaplan-Meier Plot for HT29 Xenografts Growing in Female Nude Mice


Kaplan-Meier Plot for HT29 Xenografts Growing in Female Nude Mice

 

For more information about our human tumor xenograft models, contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.

Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
May 08 - Comparability Studies for Monoclon...
May 02 - Real Time Polymerase Chain Reactio...
May 20-May 22 - San Diego, CA - 2013 American Association of Pharmaceutical Scientists ...
May 23-May 23 - East Lansing, Michigan, USA - The Ins and Outs of Transgenic Colongy Ma...

Charles River Laboratories, Inc.